tb 500 or bpc 157 BPC-157 / Tb-500 10mg BPC-157 vs TB-500 After Surgery

No sponsor, no trials

Injections: subcutaneous (under the skin) simple and effective for targeted support

Two different conditions were employed: endpoint A, where the medium was supplemented with an excipient (citrate-phosphate buffer, pH 5, Merck, Darmstadt, Germany), and endpoint B, where the medium was supplemented with cyanocobalamin (Merck) at a final concentration of 1 nM

*New patients require an initial consultation to review health history and ensure appropriate dosing and candidacy

BPC-157 Side Effects The evidence on BPC-157 risks and adverse reactions is extremely scarce

Consultado el 31 de enero de 2018